^
    1m
    Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer. (PubMed, Gynecol Oncol Rep)
    In the preclinical study, durable antitumor effect was achieved through combination treatment with Olvi-Vec and cisplatin in mouse model of PROC. Combination therapy of Olvi-Vec and platinum-doublet chemotherapy resulted in a clinically meaningful benefit in the VIRO-15 study, reversing the typical trend of deteriorating PFS, and with clinical reversal of platinum resistance. Olvi-Vec treatment can favorably modify the TME in OC and may explain the apparent reversal of platinum resistance following platinum rechallenge.Trial Registration:ClinicalTrials.gov Identifier: NCT02759588.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    cisplatin • olvimulogene nanivacirepvec (GL-ONC1)
    1m
    SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, Vir Biotechnology, Inc. | Trial completion date: Aug 2029 --> May 2032 | Trial primary completion date: Aug 2029 --> Nov 2031
    Trial completion date • Trial primary completion date
    2ms
    IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma. (PubMed, Nat Commun)
    However, elevated expression of poliovirus receptor (PVR) and the immune checkpoint T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) on tumor-infiltrating leukocytes suggests a potential resistance mechanism to virotherapy. Combining rQNestin34.5 v.2 with TIGIT blockade enhances therapeutic efficacy compared to monotherapy, identifying IDH1-R132H as a potential predictive biomarker for oncolytic virotherapy response.
    Journal • IO biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
    |
    IDH1 R132
    |
    linoserpaturev (CAN-3110)
    2ms
    VIR-2218-1006: A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFN? in Subjectsnwith Chronic Hepatitis B Virus Infection (2024-513177-48-00)
    P1/2, N=24, Completed, Vir Biotechnology Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Pegasys (pegylated interferon α -2a)
    2ms
    Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=46, Completed, Genelux Corporation | Phase classification: P1b --> P1/2
    Phase classification • IO biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • albumin-bound paclitaxel • olvimulogene nanivacirepvec (GL-ONC1)
    3ms
    ECLIPSE 2: A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (clinicaltrials.gov)
    P3, N=150, Recruiting, Vir Biotechnology, Inc.
    Trial initiation date
    3ms
    NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2030 --> Dec 2028 | Trial primary completion date: Sep 2030 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • NC410
    3ms
    EBVision: A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases (clinicaltrials.gov)
    P2, N=190, Active, not recruiting, Pierre Fabre Medicament | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tab-cel (tabelecleucel)
    3ms
    Evaluating Outcomes in Acute Promyelocytic Leukemia Patients Treated with All-Trans-Retinoic Acid and Arsenic Trioxide. (PubMed, Indian J Hematol Blood Transfus)
    Acute promyelocytic leukemia (APML) is characterized by promyelocytic leukemia retinoic acid receptor alpha (PML-RARA) fusion gene resulting from at (15;17) translocation. While, TLC significantly decreased from baseline in high risk cases to last follow-up (24 × 109/L vs. 9 × 109/L; P = 0.016). Patients with APML can be successfully treated with a combination of ATO and ATRA.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • RARA (Retinoic Acid Receptor Alpha) • CD33 (CD33 Molecule) • PML (Promyelocytic Leukemia) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    arsenic trioxide • Vesanoid (tretinoin)
    4ms
    MARCH: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P2, N=244, Completed, Vir Biotechnology, Inc. | Active, not recruiting --> Completed
    Trial completion
    4ms
    Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma. (PubMed, medRxiv)
    DOC1021 was safe, feasibly integrated within SOC, and associated with more favorable outcomes in this challenging patient population. Patients who received observation rather than reoperation for worsening MRI contrast-enhancement exhibited superior survival, suggesting an immune-reactive tumor microenvironment manifesting as pseudo-progression. These data supported initiation of a randomized Phase II trial ( NCT06805305 ) for nGBM.
    P1 data • Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)
    4ms
    QUATRO-APL: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P3, N=150, Recruiting, Quetzal Therapeutics
    New P3 trial
    |
    PML (Promyelocytic Leukemia)
    |
    Chr t(15;17)
    |
    arsenic trioxide • Vesanoid (tretinoin)